Posted by Michael Wonder on 28 Jun 2021
Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease
26 June 2021 - If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the European Union suffering from chronic kidney disease
AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union for the treatment of chronic kidney disease in adults with and without type 2 diabetes mellitus.
